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Targeting Ablation to the Distal Segment of the Main 
Renal Artery and Post-Bifurcation Branches May 
Optimize Renal Denervation (RDN)
Insufficient procedural efficacy has been proposed to ex-
plain nonresponse to renal denervation (RDN). The impact 
of different patterns of lesion placements on the efficacy and 
consistency of catheter-based radiofrequency (RF) RDN was 
examined in pigs. Increasing the number of RF lesions (4, 8, 
and 12) in the main renal artery was not sufficient, but targeted 
treatment of the renal artery branches or distal segment of 
the main renal artery resulted in markedly less variability of 
response and significantly greater reduction of both norepi-
nephrine (NE) and axon density than conventional treatment 
of only the main renal artery. Combination treatment (main 
artery plus branches) produced the greatest change in renal 
NE and axon density with the least heterogeneity. The changes 
lasted through 28 days post-treatment (Mahfoud F et al, J Am 
Coll Cardiol 2015; 66:1766-1775).
High Levels of Cardiorespiratory Fitness in Midlife 
Confer Lower Mortality, Use of Health Care Resources, 
and Health Care Costs Later in Life 
Among 19,571 healthy individuals who underwent car-
diorespiratory fitness assessment at a mean age of 49 years, 
over 126,388 person-years of follow-up, average annual health 
care costs were significantly lower for participants aged >65 
years with high than low midlife fitness in both men and 
women. Average annual health care costs in later life were 
incrementally lower per MET achieved in midlife in men and 
women. The authors concluded that higher cardiorespiratory 
fitness in middle age is strongly associated with lower health 
care costs at an average of 22 years later in life, independent 
of cardiovascular risk factors (Bachmann JM et al, J Am Coll 
Cardiol 2015; 66:1876-1885).
Moderate Physical Activity is Associated with  
a Reduced Risk of Atrial Fibrillation (AF)  
in Middle-Aged and Elderly Women
According to a Swedish study comprising 36,513 AF-free 
women (aged 49–83, median 60 years) during a median of 12 
years, 2915 cases of AF were diagnosed. The risk of AF de-
creased with increasing levels of leisure-time exercise at study 
entry (relative risk - RR 0.85, for ≥4 h/week vs <1 h/week) and 
walking/bicycling (RR 0.81, for ≥40 min/day vs almost never) 
(Drca N et al, Heart 2015; 101:1627-1630).
Very Late Thrombosis of Bioresorbable Coronary 
Scaffolds Despite Antiplatelet Therapy, Possibly 
Related to Scaffold Discontinuity and Restenosis, 
Implies an Extended Period of Vulnerability  
to Ischemic Events
Four patients presented with very late scaffold thrombosis 
(VLScT) at 44, 19 (2 cases), and 21 months, after implantation 
of an Absorb Bioresorbable Vascular Scaffold. At the time of 
VLScT, all patients were taking low-dose aspirin, and 2 patients 
were also taking prasugrel. Optical coherence tomography 
(OCT) showed malapposed scaffold struts surrounded by 
thrombus in 7.1%, 9%, and 8.9% of struts in 3 cases. Scaffold 
discontinuity with struts in the lumen center was the cause 
of malapposition in 2 cases. Uncovered scaffold struts with 
superimposed thrombus were the predominant findings in 1 
case. OCT percent area stenosis at the time of VLScT was high 
in 2 cases (71-75%) without evidence of excessive neointimal 
hyperplasia. Thrombus aspirate analysis showed persistence 
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of intracoronary polymer fragments in 1 case (Räber L et al, 
J Am Coll Cardiol 2015; 66:1901-1914). 
Meta-Analysis: Macrolide Antibiotics Increase Rates of 
Ventricular Tachyarrhythmias, Sudden Cardiac Death, 
and Cardiovascular Death, but not All-Cause Deaths
Meta-analysis of 33 studies involving 20,779,963 partici-
pants indicated that patients who took macrolides, compared 
with those who did not, experienced an increased risk of 
developing sudden cardiac death (SCD) or ventricular tach-
yarrhythmias (VTAs) (relative risk - RR: 2.42), SCD (RR: 
2.52), and cardiovascular death (RR: 1.31). No association 
was found between macrolides use and all-cause death or any 
cardiovascular events. The RRs associated with SCD or VTAs 
were 3.40 for azithromycin, 2.16 for clarithromycin, and 3.61 
for erythromycin, respectively. RRs for cardiovascular death 
were 1.54 for azithromycin and 1.48 for clarithromycin. No 
association was noted between roxithromycin and adverse 
cardiac outcomes (Cheng Y-J et al, J Am Coll Cardiol 2015; 
66:2173-2184).
Most Patients With Symptomatic Carcinoid Valvular 
Heart Disease Have Symptom and Survival Benefit 
from Valve Replacement Especially when Operated 
Before Advanced Right-Sided Heart Failure Develops
Among 195 patients with carcinoid heart disease (CaHD) 
(70% NYHA class III or IV), all having tricuspid valve replace-
ment (159 bioprostheses, 36 mechanical), and 157 pulmonary 
valve operation, with 4-23% also having other concomitant 
operations, there were 20 perioperative deaths (10%). After 
year 2000, perioperative mortality was 6%. Survival rates at 
1, 5, and 10 years were 69%, 35%, and 24%, respectively. 
Overall mortality was associated with older age, cytotoxic 
chemotherapy, and tobacco use; 75% of survivors had symp-
tomatic improvement at follow-up (Connolly HM et al, J Am 
Coll Cardiol 2015; 66:2189-2196).
ROCKET AF: In Patients With Atrial Fibrillation (AF) 
and Additional Stroke Risk Factors, Anti-coagulation 
With Rivaroxaban is Associated With a Higher Rate  
of Major or Non-Major GI Bleeding than Warfarin,  
but Similar Rate of Most Severe GI Bleeding
Among 14,236 patients, 684 experiencing gastrointestinal 
(GI) bleeding during follow-up, there was a significantly higher 
rate of major or non-major clinical GI bleeding in rivaroxaban- 
vs warfarin-treated patients (3.61 events/100 patient-years vs 
2.60 events/100 patient-years; hazard ratio: 1.42). Severe GI 
bleeding rates were similar between treatment arms, and fatal 
GI bleeding events were rare. Independent clinical factors most 
strongly associated with GI bleeding were baseline anemia, 
history of GI bleeding, and long-term aspirin use (Sherwood 
MW et al, J Am Coll Cardiol 2015; 66:2271-2281).
In Patients With Severe, Symptomatic Secondary 
Tricuspid Regurgitation (TR) at High Risk for Surgery, 
Transcatheter Reduction Therapy May  
be an Acceptable Alternative Strategy
The transcatheter Forma Repair System (Edwards Lifes-
ciences, Irvine, Ca, USA), designed to provide a surface for 
native leaflet coaptation to reduce TR by occupying the re-
gurgitant orifice area, was employed via the left axillary vein in 
7 high-risk patients with severe TR and clinical signs of heart 
failure (NYHA class II-IV) who were declined for surgery 
(logistic EuroSCORE 25.7±17.4%). The device consists of 
a spacer (a foam-filled polymer balloon) and a rail that is an-
chored at the right ventricular apex. Device implantation was 
successful without procedural complications in all patients, with 
significant reductions in TR severity (moderate in 3 and mild 
in 4 patients). Median hospital stay was 4 days. At 30 days, all 
patients but 1 had improvement in NYHA status (to class II) 
with marked reduction in peripheral edema and moderate TR 
(Campelo-Parada F et al, J Am Coll Cardiol 2015; 66:2475-2483).
CRT-D is Associated with a Lower Risk of Heart 
Failure Hospitalization or Death Among Patients With 
Stages 3-5 Chronic Kidney Disease, Including Those on 
Dialysis, Than Management With Defibrillators Alone
Among 10,946 cardiac resynchronization therapy (CRT)-
eligible patients (ejection fraction <35%, QRS >120 ms, NYHA 
class III/IV) with stage 3 to 5 chronic kidney disease (CKD), 
CRT-D use (n=9,525) compared with ICD only (n=1421) was 
associated with a reduction in heart failure (HF) hospitalization 
or death (hazard ratio - HR: 0.84; p <0.0001), death (HR: 0.85; 
p <0.0004), and HF hospitalization alone (HR: 0.84; p <0.009). 
Subgroup analyses suggested that CRT was associated with 
a reduced risk of HF hospitalization and death across CKD 
classes. The incidence of in-hospital, short-term, and mid-term 
device-related complications did not vary across CKD stages 
(Friedman DJ et al, J Am Coll Cardiol 2015; 66:2618-2629).
NORDIC ICD Trial: Defibrillation Testing During 
Initial ICD Implantation is no Longer Required for 
Routine Left-Sided ICD Implantation
Among 1077 patients having initial ICD implantation 
with (n=540) or without (n=537) defibrillation (DF) test-
ing (all ICD shocks programmed to 40 J irrespective of DF 
test results), over a mean of 22.8 months, first shock efficacy 
(FSE) was found to be non-inferior in patients with an ICD 
implanted without a DF test, with a difference in FSE of 
3% in favour of the no-DF test (Pnon-inferiority <0.001 for the 
pre-defined non-inferiority margin of −10%). A total of 112 
procedure-related serious adverse events occurred within 30 
days in 94 patients (17.6%) tested compared with 89 events 
in 74 patients (13.9%) not tested (P=0.095) (Bänsch D et al, 
Eur Heart J 2015; 36:2500-2507).
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In Patients With Ventricular Arrhythmias (VAs) that 
Exhibit LBBB and Inferior Axis, Pace Mapping in the 
RV Outflow Tract (RVOT) May not Identify the VA 
Focus. In Such Patients, Particularly When Ablation 
Has Failed, Mapping Performed at the Pulmonary 
Sinus Cusp (PSC) Identifies VAs that Can be 
Successfully Ablated
Among 218 patients undergoing successful endocardial 
ablation of idiopathic VAs with a left bundle branch block 
(LBBB) morphology and inferior axis, 24 patients had VAs 
originating from the PSC. In the first 7, initial ablation per-
formed in the RVOT failed but produced a small change in the 
QRS morphology in 3 patients. In all 24 patients, the earliest 
activation was eventually identified in the PSC, where a sharp 
potential was recorded preceding the QRS onset by 28.2±2.9 
ms. The successful ablation site was in the right cusp (RC) 
in 10 patients (42%), the left cusp (LC) in 8 (33%), and the 
anterior cusp (AC) in 6 (25%). ECG analysis showed that RC-
VAs had unique ECG characteristics (larger R-wave in lead I 
and a smaller aVL/aVR ratio of Q-wave amplitude compared 
with AC-VAs and LC-VAs; R-wave amplitude in inferior leads 
was smaller in VAs localized in the RC than in the LC but did 
not differ between VAs from the AC and LC (Liao Z et al, J 
Am Coll Cardiol 2015; 66:2633-2644).
Revascularization, not Necessarily by PCI, of Chronic 
Total Occlusion (CTO), is Associated with Improved 
Long-Term Survival Relative to Medical Therapy
Among 1957 patients, a CTO was treated by PCI in 405 
(20.7%), medical therapy in 667 (34.1%), and coronary bypass 
in 885 (45.2%) patients. Of those treated by PCI or medical 
therapy, propensity score matching identified 294 pairs of 
patients; PCI was successful in 177 patients (60.2%). All-cause 
mortality at 5 years was 11.6% for CTO PCI and 16.7% for 
medical therapy, hazard ratio-HR 0.63 (p=0.052). The com-
posite of 5-year death or MI occurred in 13.9% of the CTO 
PCI group and 19.6% in the medical therapy group, HR 0.64 
(p=0.043). Among the CTO PCI group, if CTO was revascu-
larized by any means, 5-year mortality was 10.6% vs 18.3% in 
those not revascularized in the medical therapy group, HR 
0.50 (p=0.016) (Ladwiniec A et al; Heart 2015;101:1907-1914). 
CvLPRIT Cardiovascular Magnetic Resonance (CMR) 
Substudy: In Patients With STEMI and Multivessel 
Disease, Complete Revascularization is Associated with 
a Small Increase (12%) in the Risk of Type 4a MIs, but 
Similar Total Infarct Size, Compared With a Strategy 
Addressing Only the Infarct-Related Artery (IRA)
Among 203 of the 296 patients in the main trial (98 complete 
revascularization and 105 IRA-only), having a pre-discharge 
CMR, total infarct size was similar in the two groups. The 
complete revascularization group had an increase in non-IRA 
MI on the pre-discharge CMR (22 of 98 vs 11 of 105, p=0.02). 
There was no difference in total infarct size or ischemic burden 
between treatment groups at follow-up CMR (McCann GP et 
al, J Am Coll Cardiol 2015; 66:2713-2724).
CHASE-AF: Pulmonary Vein Isolation (PVI) Should 
be the Initial Strategy of Ablation in Patients With 
Persistent AF, Because More Extensive Ablation Has 
no Better Rhythm Control Outcomes 
Two strategies of catheter ablation were compared in 205 
patients (mean age 62 years) with persistent atrial fibrillation 
(AF): pulmonary vein isolation (PVI) and a stepwise ap-
proach (full defrag) of PVI, ablation of complex fractionated 
electrograms, and additional linear ablation lines for atrial 
tachycardias in patients with persistent AF after PVI. Patients 
were prospectively randomized to either PVI alone (n=78) or 
full defrag (n=75), with 52 patients not randomized due to AF 
termination with the original PVI. A total of 241 ablations were 
performed (mean: 1.59 in the PVI-alone group, 1.55 in the 
full-defrag group). With the stepwise approach, termination of 
AF occurred in 45 (60%) patients. However, arrhythmia-free 
survival did not differ whether patients underwent single or 
multiple procedures (p=NS). Procedure duration, fluoroscopy 
time, and radiofrequency duration were significantly longer in 
the full-defrag group (all p <0.001) (Vogler J et al, J Am Coll 
Cardiol 2015; 66:2743-2752).
New Oral Anticoagulants (NOACs) and Left Atrial 
Appendage Closure (LAAC) are Cost-Effective Over 
Warfarin for Stroke Risk Reduction in Patients With 
Nonvalvular AF / LAAC Proved to be the Most  
Cost-Effective Treatment
Using a Markov model and information from PROTECT 
AF 4-year data and meta-analyses of warfarin and NOACs, it 
was shown that relative to warfarin, LAAC was cost-effective 
at 7 years ($42,994/quality-adjusted life-years - QALY), and 
NOACs were cost-effective at 16 years ($48,446/QALY). LAAC 
was dominant over NOACs by year 5 and warfarin by year 
10. At 10 years, LAAC gave more QALYs than warfarin and 
NOACs (5.855 vs 5.601 vs 5.751, respectively). In sensitivity 
analyses, LAAC remained cost-effective relative to warfarin 
($41,470/QALY at 11 years) and NOACs ($21,964/QALY at 10 
years) (Reddy VY et al, J Am Coll Cardiol 2015; 66:2728-2739).
VISTA Trial: Substrate-Based Ablation is Superior 
to Targeting Only Clinical and Stable Ventricular 
Tachycardias (VTs) in Ischemic Cardiomyopathy, and 
Confers a Significant Reduction of Combined Incidence 
of Rehospitalization and Mortality 
Subjects with ischemic cardiomyopathy and hemodynami-
cally stable VT were randomized to clinical ablation (n=60) vs 
substrate-based ablation that targeted all “abnormal” electro-
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grams in the scar (n=58). At 1 year, 9 (15.5%) in the substrate-
based and 29 (48.3%) patients in the clinical VT ablation group 
had VT recurrence (p <0.001). More patients undergoing 
clinical VT ablation (58%) were on antiarrhythmic drugs after 
ablation vs substrate-based ablation (12%; p <0.001). Seven 
(12%) patients with substrate ablation and 19 (32%) with clini-
cal ablation required rehospitalization (p=0.014). Mortality 
at 1 year was 11.9%; 8.6% in the substrate ablation and 15% 
in the clinical ablation group (p=0.21). Combined incidence 
of rehospitalization and mortality was significantly lower with 
substrate ablation (p=0.003). Periprocedural complications 
were similar (p=NS) (Di Biase L et al, J Am Coll Cardiol 
2015; 66:2872-2882).
EVEREST II: The 5-Year Results Support the 
Superiority of Surgery in Reducing Mitral 
Regurgitation (MR) but Also the Long-Term Safety 
of the Mitraclip and the Durability of MR Reduction 
After Percutaneous Repair / Although Patients Treated 
With Percutaneous Repair More Commonly Required 
Surgery for Residual MR in the First Year, Between 
Years 1-5, there were Comparably Low Rates of 
Surgery for Valve Dysfunction
In EVEREST II, treatment of MR with the MitraClip 
showed superior safety compared with surgery, but less effective 
reduction in MR at 1 year. At 5 years, the rate of the composite 
endpoint of freedom from death, surgery, or 3+/4+ MR in the 
as-treated population was 44.2% in the percutaneous repair 
and 64.3% in the surgical group (p=0.01); difference driven by 
increased rates of 3+ to 4+ MR (12.3% vs 1.8%; p=0.02) and 
of surgery (27.9% vs 8.9%; p=0.003) with percutaneous repair. 
After percutaneous repair, 78% of surgeries were performed 
within the first 6 months. Beyond 6 months, rates of surgery 
and moderate-to-severe MR were comparable between groups; 
as well as 5-year mortality rates (20.8% and 26.8%) (Feldman 
T et al, J Am Coll Cardiol 2015; 66:2844-2854).
CURRENT AS Registry: Earlier Aortic Valve 
Replacement (AVR) in Patients With Asymptomatic 
Severe Aortic Stenosis (AS) is Associated with Lower 
Long-Term Risk of Hospitalization for HF or All-Cause 
Mortality Compared With Currently Recommended by 
Guidelines to Await Symptom Onset 
Data from 1,808 asymptomatic severe AS patients having 
AVR (n=291) or conservative strategies (n=1,517) and from 
a propensity score–matched cohort of 582 patients (n=291 in 
each group) indicated that the cumulative 5-year incidences of 
all-cause death (15.4% vs 26.4%, p=0.009) and heart failure 
(HF) hospitalization (3.8% vs 19.9%, p <0.001) were sig-
nificantly lower in the initial AVR group. In the conservative 
group, AVR was performed in 41% of patients during follow-
up (Taniguchi T et al, J Am Coll Cardiol 2015; 66:2827-2838). 
STS/ACC TVT Registry: Technological Advances in 
Device Configuration, Smaller Catheter Sizes, and 
Patient-Specific Access Site Selection Can Lower Risk 
of Extracardiac Complications in Patients Undergoing 
TAVI/ However, these Patients Have Multiple Co-
morbidities, Including Advanced Age, and the Risk 
of Periprocedural Stroke Remains an Important 
Concern
Comparison of 2 time periods (2012 & 2013) among 26,414 
TAVI procedures (by 31/12/2014) in TVT Registry revealed 
that TAVI patients remain elderly (mean age 82), with multiple 
comorbidities reflected by a high mean STS score (8.34%), were 
highly symptomatic (NYHA class III/IV in ~83%), frail (slow 
5-m walk test in ~82%), and have poor self-reported health 
status. Procedure performance is changing, with an increased 
use of moderate sedation (from 1.6% to 5.1%) and increase in 
femoral access (~67% in 2014). Vascular complication rates 
are decreasing (from 5.6% to 4.2%), whereas site-reported 
stroke rates remain stable at 2.2% (Holmes DR et al, J Am 
Coll Cardiol 2015; 66:2813-2823). 
FreezeAF Study: Noninferiority of Cryoballoon (CB) 
Versus Open Irrigated Radiofrequency (RF) Ablation 
in Patients With Paroxysmal Atrial Fibrillation (PAF)
A total of 315 PAF patients were randomly assigned to RF 
(n=159) or CB (n=156) ablation. Freedom from arrhythmia 
with absence of persistent complications at 1 year was achieved 
by 70.7% with RF and 73.6% with CB (multiple procedure 
success), including 31 redo procedures in each group (19.5% 
of RF vs 19.9% of CB; P=NS). Rates at 6 months were 63.1% 
and 64.1% for the RF and CB groups (single procedure 
success), and noninferiority was confirmed (risk difference, 
0.010; P=0.002). Periprocedural complications for the index 
procedure were more frequent in the CB group (5% RF, 12.2% 
CB; P=0.022) with a significant difference in phrenic nerve 
palsies (0% RF, 5.8% CB; P=0.002) (Luik A et al, Circulation 
2015; 132:1311-1319).
Meta-Analysis of Case-Control Studies: Significant 
Association Between Recent Respiratory Infection 
and Acute Myocardial Infarction (AMI) / Estimated 
Vaccine Effectiveness Against AMI was Comparable 
with the Efficacy of Currently Accepted Therapies for 
Secondary Prevention of AMI 
According with 16 case–control studies (8 on influenza 
vaccination, 10 on influenza infection and AMI), recent 
influenza infection, influenza-like illness or respiratory tract 
infection was more likely in AMI cases, with a pooled odds 
ratio - OR 2.01. Influenza vaccination was associated with 
AMI, with a pooled OR of 0.71, equating to an estimated 
vaccine effectiveness of 29% against AMI (Barnes M et al, 
Heart 2015; 101:1738-1747). 
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Treatment With Colchicine in Patients With STEMI 
Undergoing Primary PCI is Associated With Smaller 
Infarct Size, as Defined by Both Biomarker Release 
and MRI-Late Gadolinium Enhancement (LGE) 
Patients (n=151) presenting with ST-segment–elevation 
myocardial infarction (STEMI) ≤12 hours from pain onset 
(treated with primary PCI) were randomly assigned to colchi-
cine (n=77) or placebo (n=74) for 5 days. A subset of patients 
(n=60) underwent cardiac MRI-LGE 6-9 days after the index 
STEMI. The area under the CK-MB curve was 3144 ng·h–
1·mL–1 in the colchicine group vs 6184 ng·h–1·mL–1 in controls 
(P <0.001). Indexed MRI–LGE defined infarct size was 18.3 
mL/1.73 m2 in the colchicine group (n=31) vs 23.2 mL/1.73 m2 
in controls (n=29) (P=0.019). The relative infarct size (as a 
proportion to left ventricular myocardial volume) was 13% and 
19.8%, respectively (P=0.034) (Deftereos S et al, Circulation 
2015; 132:1395-1403).
Taiwanese Database: Risk of Mortality was Lower for 
AF Patients Receiving Rate-Control With Β-Blockers 
or Calcium Channel Blockers (Β-Blockers Conferred 
the Largest Risk Reduction), While Digoxin Use was 
Associated With Greater Mortality
Over a mean of ~5 years, among 43,879 patients with atrial 
fibrillation (AF) receiving β-blockers, 18,466 receiving calcium 
blockers, and 38,898 receiving digoxin, 88,263 patients (32.7%) 
died. Compared to a reference group of 168,678 subjects who 
did not receive any rate-control drug, the risk of mortality was 
lower in patients receiving β-blockers (hazard ratio – HR =0.76) 
and calcium channel blockers (HR=0.93). On the contrary, 
the digoxin group had a higher risk of mortality with an HR 
of 1.12 (Chao T-F et al, Circulation 2015; 132:1604-1612).
WEARIT-II Registry: High Rate of Sustained 
Ventricular Tachyarrhythmias (VTAs) at 3 Months  
in Patients At-Risk Who are not Eligible for an ICD / 
The Wearable Cardioverter Defibrillator (WCD)  
Can Protect Patients During this Period 
A total of 2000 patients (median age 62 years; median ejec-
tion fraction 25%) with ischemic (n=805, 40%), or nonischemic 
cardiomyopathy (n=927, 46%), or congenital /inherited heart 
disease (n=268) received a wearable cardioverter defibrillator 
(WCD) for a median of 90 days, with median daily use of 22.5 
h. There was a total of 120 sustained VTAs in 41 patients, of 
whom 54% received appropriate WCD shock (10 patients or 
0.5% received inappropriate therapy). Rate of sustained VTAs 
by 3 months was 3% among patients with ischemic cardio-my-
opathy and congenital/inherited heart disease, and 1% among 
nonischemic patients (P=0.02). Finally, 840 patients (42%) 
were implanted with an ICD. The most frequent reason not to 
implant an ICD following WCD use was improvement in ejec-
tion fraction (Kutyifa V et al, Circulation 2015; 132:1613-1619). 
Descending Thoracic or Thoracoabdominal Aortic 
Aneurysm: Risk of Rupture Starts to Increase With 
a Diameter >5.0 - 5.5 cm / Uncertain Whether 
Aneurysm Repair in this Range Leads to Overall 
Benefit
Of 257 patients (age, 72.4±10.5 years; 143 women) with 
descending thoracic or thoracoabdominal aortic aneurysm 
(baseline mean maximal diameter 52.4±10.8 mm, with 103 
patients having diameters ≥55 mm) without a history of aortic 
dissection in whom surgical intervention was not undertaken, 
over 2 years, definite and possible aortic events occurred in 19 
(7.4%) and 31 (12.1%) patients, respectively. Maximal aortic 
diameter at baseline was the only significant predictor of aortic 
events (hazard ratio=1.12). Estimated rates of definite aortic 
events within 1 year were 5.5%, 7.2%, and 9.3% for aortic 
diameters of 50, 55, and 60 mm, respectively (Kim JB et al, 
Circulation 2015; 132:1620-1629).
Meta-analysis: Doses of Physical Activity (PA) in 
Excess of the Guideline-Recommended Minimum 
PA Levels May be Required for More Substantial 
Reductions in Heart Failure (HF) Risk 
In 12 prospective cohort studies with 20,203 HF events 
among 370,460 patients (53.5% women; median follow-up, 13 
years), the highest levels of PA were associated with reduced 
risk of HF (hazard ratio – HR for highest vs lowest PA, 0.70). 
Compared with patients reporting no leisure-time PA, those 
who engaged in guideline-recommended minimum levels of PA 
(500 MET-min/wk; 2008 US guidelines) had modest reductions 
in HF risk (HR, 0.90). However, a higher risk reduction was 
observed among patients who engaged in PA at twice (HR for 
1000 MET-min/wk, 0.81) and 4 times (HR for 2000 MET-min/
wk, 0.65) the minimum guideline-recommended levels (Pandey 
A et al, Circulation 2015; 132:1786-1794).
CARDIA Study: Higher Intake of Fruits  
and Vegetables (F/V) During Young Adulthood  
was Associated With Lower Odds of Prevalent 
Coronary Artery Calcium After 20 Years  
of Follow-Up / Important to Establish a High  
Intake of F/V as Part of a Healthy Dietary  
Pattern Early in Life
Among the study participants (n=2506) (mean age at 
baseline 25.3 years; 62.7% female), higher intake of F/V was 
associated with a lower prevalence of coronary artery calcium 
(measured at year 20 using computed tomography): odds 
ratio - OR, 0.78, and 0.74, from the lowest to the highest ter-
tile of F/V, P value for trend <0.001. There was attenuation 
of the association between F/V and coronary artery calcium 
after adjustment for other dietary variables, but the trend 
remained significant: OR, 0.84, and 0.92, P value for trend 
<0.002 (Miedema MD et al, Circulation 2015; 132:1990-1998). 
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PATH Registry: Better Survival and Neurological 
Outcome With Therapeutic Hypothermia for Post–
Cardiac Arrest Patients with an Initial Nonshockable 
Rhythm
Among 519 patients after in- and out-of-hospital cardiac 
arrest with nonshockable initial rhythms, 201 propensity score–
matched pairs (mean age 63±17 years, 51% male; 60% with 
initial pulseless electric activity) were compared. Survival to 
hospital discharge was greater in patients who received thera-
peutic hypothermia (TH) (17.6% vs 28.9%; P <0.01), as was a 
discharge Cerebral Performance Category of 1 to 2 (13.7% vs 
21.4%; P=0.04). Patients who received TH were more likely 
to survive (odds ratio, 2.8) and to have better neurological 
outcome (odds ratio, 3.5) than those that did not receive TH 
(Perman SM et al, Circulation 2015; 132:2146-2151).
Outcomes are Better with Basic (BLS) than Advanced 
Life Support (ALS) for Several Out-of-Hospital 
Medical Emergencies 
In a 20% random sample of Medicare beneficiaries from 
non-rural areas with major trauma, stroke, acute myocardial 
infarction (AMI), or respiratory failure, except in cases of 
AMI, patients showed superior outcomes with BLS despite 
being older and having more comorbidities. In propensity score 
analysis, survival to 90 days among patients with trauma, stroke, 
and respiratory failure was higher with BLS than ALS (6.1% 
points for trauma; 7% points for stroke; and 3.7% points for 
respiratory failure). Patients with AMI did not have differences 
in survival at 30 days but had better survival at 90 days with 
ALS (1% point). Neurologic functioning favored BLS for all 
diagnoses. Instrumental variable analysis for trauma and stroke 
had similar results, showed no survival differences between BLS 
and ALS for respiratory failure, and showed better survival 
at all time points with BLS than ALS for patients with AMI 
(Sanghavi P et al, Ann Intern Med. 2015; 163:681-690).
Potassium Channel Blockade May Enhance Atrial 
Fibrillation (AF)–Selective Antiarrhythmic Effects of 
Optimized State-Dependent Sodium Channel Blockade
In a mathematical model, combining optimized Na+-
channel blocker with IKr block increased rate-dependent and 
atrium-selective peak INa reduction, increased AF selectivity, 
and more effectively terminated AF compared with optimized 
Na+-channel blocker alone. Combining optimized Na+-channel 
blocker with IKur block had similar effects but without IKr block–
induced ventricular action potential prolongation. Consistent 
with the mathematical model, in coronary-perfused canine 
hearts, the addition of dofetilide (selective IKr blocker) to 
pilsicainide (selective INa blocker) produced enhanced atrium-
selective effects on maximal phase 0 upstroke and conduction 
velocity. Furthermore, pilsicainide plus dofetilide had higher 
AF termination efficacy than pilsicainide alone. Pilsicainide 
alone had no significant effect on AF inducibility, whereas 
pilsicainide plus dofetilide rendered AF noninducible (Aguilar 
M et al, Circulation 2015; 132:2203-2211).
3 Large Prospective Cohorts: Higher Consumption 
of Coffee, either Caffeinated or Decaffeinated, was 
Associated With Lower Risk of Total Mortality
The associations of consumption of total, caffeinated, and 
decaffeinated coffee with risk of subsequent total and cause-
specific mortality were examined among 74,890 women in the 
Nurses’ Health Study (NHS), 93,054 women in the Nurses’ 
Health Study II, and 40,557 men in the Health Professionals 
Follow-up Study. During 4,690,072 person-years of follow-up, 
19,524 women and 12,432 men died. Compared with nondrink-
ers, coffee consumption of 1-5 cups/day was associated with 
lower risk of mortality, whereas coffee consumption of >5 
cups/day was not. However, when restricting to never smokers 
compared with nondrinkers, the hazard ratios of mortality were 
0.94 for <1 cup/day, 0.92 for 1.1 to 3.0 cups/day, 0.85 for 3.1-
5.0 cups/day, and 0.88 for >5 cups per day (P value for trend 
<0.001). Significant inverse associations were observed for 
caffeinated (P <0.001) and decaffeinated coffee (P=0.022). 
Significant inverse associations were observed between coffee 
consumption and deaths attributed to cardiovascular disease, 
neurologic diseases, and suicide. No significant association 
between coffee consumption and total cancer mortality was 
found (Ding M et al, Circulation 2015; 132:2305-2315).
Among Patients With Continuous-Flow Left 
Ventricular Assist Devices, Restoration of Pulsatile 
Flow Through Modulations in Pump Speed Leads to 
Decline in Muscle Sympathetic Nerve Activity (MSNA)
Reductions in pump speed in 13 patients (10 men/3 women, 
54±14 years) with Heartmate II continuous-flow left ven-
tricular assist devices led to increases in pulse pressure (high 
vs low speed: 17±7 vs 26±12 mm Hg; P <0.01), distension of 
the carotid artery, and carotid arterial wall tension (P <0.05 
for all measures). In addition, MSNA was reduced (high vs 
low speed: 41±15 vs 33±16 bursts/minute; P <0.01) despite a 
reduction in mean arterial pressure and was inversely related 
to pulse pressure (P=0.037) (Cornwell WK et al, Circulation 
2015; 132:2316-2322).
40-Year Analysis of >500 Patients With Primary 
Malignant Cardiac Tumors (PMCTs): MPCTs are 
Extremely Rare and Continue to be Associated With 
Poor Prognosis / Over the Past 5 Decades, Incidence 
and Survival Appear to Have Increased
From a total of 7,384,580 cases of cancer registered in the 
National Cancer Institute, 551 PMCTs (0.008%) were iden-
tified with an incidence of 34 cases per 100 million persons, 
increased over time (25.1 in 1973–1989, 30.2 in 1990–1999, 
CARDIOLOGY NEWS
7
and 46.6 in 2000–2011). Most patients are female (54.1%) 
and white (78.6%) with median age at diagnosis of 50 years. 
The most common PMCTs are sarcomas (n=357, 64.8%), 
lymphomas (n=150, 27%) and mesotheliomas (n=44, 8%), 
mostly diagnosed with biopsy (96.8%). Use of chemotherapy 
is not documented; 19% received radiation and 44% had 
surgery. After a median of 80 months, 413 patients had died. 
The 1-, 3-, and 5-year survival rates were 46%, 22%, and 
17% and have improved over the eras, with 1-, 3-, and 5-year 
survival rates of 32%, 17%, and 14% for 1973-1989 and 50%, 
24%, and 19% for 2000-2011 (P=0.009). Cardiac sarcomas 
and mesotheliomas are the most lethal PMCTs. Patients with 
cardiac lymphomas and sarcomas are younger and have worse 
survival than patients with extracardiac disease of similar 
histopathology (P <0.001) (Oliveira GH et al, Circulation 
2015; 132:2395-2402).
Transvenous Lead Removal (TLR): Complication 
Rate in Patients Undergoing TLR was Higher Than 
Previously Reported Related to Female Gender and 
Device Infections but not to Hospital Volume 
Among 91,890 TLR procedures in the US, in-hospital death 
(2.2%), hemorrhage requiring transfusion (2.6%), vascular 
complications (2.0%), pericardial complications (1.4%), open 
heart surgery (0.2%), and postoperative respiratory failure 
(2.4%) were recorded. Independent predictors of complica-
tions were female gender and device infections. Hospital 
volume was not independently associated with higher com-
plications. There was a significant rise in overall complication 
rates over the study period (Deshmukh A et al, Circulation 
2015; 132:2363-2371). 
TUXEDO–India Trial: In Patients With Diabetes and 
Coronary Artery Disease Undergoing PCI, Paclitaxel-
Eluting Stents were Inferior to Everolimus-Eluting 
Stents, with Higher Rates of Target-Vessel Failure, 
Myocardial Infarction, Stent Thrombosis, and Target-
Vessel Revascularization at 1 Year
Among 1830 patients with diabetes and coronary artery 
disease who were undergoing PCI randomly assigned to re-
ceive either a paclitaxel-eluting stent or an everolimus-eluting 
stent, at 1 year, paclitaxel-eluting stents did not meet the 
criterion for noninferiority to everolimus-eluting stents with 
respect to the primary end point (rate of target-vessel failure, 
5.6% vs 2.9%; relative risk, 1.89; P=0.38 for noninferiority). 
There was a higher 1-year rate in the paclitaxel-eluting stent 
group of target-vessel failure (P=0.005), spontaneous myo-
cardial infarction (3.2% vs 1.2%, P=0.004), stent thrombosis 
(2.1% vs 0.4%, P=0.002), target-vessel revascularization 
(3.4% vs 1.2%, P=0.002), and target-lesion revascularization 
(3.4% vs 1.2%, P=0.002) (Kaul U et al, N Engl J Med 2015; 
373:1709-1719).
ABSORB III Study: Everolimus-Eluting Bioresorbable 
Scaffolds are Non-Inferior to Everolimus-Eluting 
Cobalt–Chromium Stents with Respect to Target-
Lesion Failure (Cardiac Death, Target-Vessel 
Myocardial Infarction, or Ischemia-Driven Target-
Lesion Revascularization) at 1 Year
Among 2008 patients with stable or unstable angina as-
signed to receive an everolimus-eluting bioresorbable vascular 
(Absorb) scaffold (n=1322) or an everolimus-eluting cobalt–
chromium (Xience) stent (n=686), target-lesion failure at 1 
year occurred in 7.8% in the Absorb and 6.1% in the Xience 
group (P=0.007 for noninferiority; P=0.16 for superiority). 
There was no significant difference between the Absorb and 
the Xience group in cardiac death (0.6% vs 0.1%; P=NS), 
target-vessel MI (6.0% vs 4.6%; P=NS), or ischemia-driven 
target-lesion revascularization (3% vs 2.5%; P=NS). Device 
thrombosis within 1 year occurred in 1.5% in the Absorb group 
and in 0.7% in the Xience group (P=NS) (Ellis SG et al, N 
Engl J Med 2015; 373:1905-1915).
BIOSOLVE-II First-In-Man Trial: Implantation  
of the Second-Generation Drug-Eluting Absorbable 
Metal Scaffold (DREAMS 2G Device) in De-Novo 
Coronary Lesions is Feasible, With Favourable Safety 
and Performance Outcomes at 6 Months, and Could  
be an Alternative to Absorbable Polymeric Scaffolds
In 123 patients (123 lesions) receiving a novel second-
generation drug-eluting absorbable metal scaffold (DREAMS 
2G), at 6 months, in-segment late lumen loss was 0.27+0.37 
mm, and angiographically discernable vasomotion was docu-
mented in 20 (80%) of 25 patients. Intravascular ultrasound 
showed a preservation of the scaffold area (6.24+1.15 mm2 
post-procedure vs 6.21+1.22 mm2 at 6 months) with a low 
neointimal area (0.08+0.09 mm2), and optical coherence to-
mography did not detect any intraluminal mass. Target lesion 
failure occurred in 4 (3%) patients: one (<1%) patient died 
from cardiac death, 1 (<1%) patient had periprocedural MI, 
and 2 (2%) patients needed clinically driven target lesion revas-
cularization. No definite or probable scaffold thrombosis was 
observed (Haude M et al, Lancet 2016; 387, No. 10013:31–39). 
A Cohort US Study on Early Repolarization: J Waves 
and QRS Slurs did not Exhibit an Increased Risk for 
Cardiovascular Death in Long-Term Follow-up
In veterans <56 years (~90% men) who had resting 12-lead 
ECG, over a median follow-up of 17.5 years, 859 cardiovascular 
deaths occurred. Of 20,661 ECGs, 4219 (20%) had J waves or 
QRS slurs in the inferior (3318 or 78.6%) and/or lateral leads 
(1701 or 40.3%). The upper bound of differences in risk for 
cardiovascular death from any of the J-wave or QRS slur pat-
terns suggests that an increased risk can be safely ruled out 
(inferior, −0.77%; lateral, −1.07%) (Pargaonkar VS et al, Ann 
Intern Med 2015; 163:747-755).
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COURAGE Trial (15-Year Follow-up): Among Patients 
With Stable Ischemic Heart Disease, Objective 
Evidence of Ischemia, Significant Coronary Disease, 
and a Substantial Risk of Death (Mortality ~4%/Year), 
there was no Difference in Long-Term Survival With an 
Initial Strategy of Optimal Medical Therapy Plus PCI 
Compared With Optimal Medical Therapy Alone
In the COURAGE trial, an initial management strategy 
of optimal medical therapy alone compared with optimal 
medical therapy plus PCI among 2287 patients with stable 
ischemic heart disease did not differ in clinical outcome over 
a median follow-up period of 4.6 years. Extended (15-year) 
survival information was available for 1211 patients (53% of 
the original group). The median follow-up for all patients 
was 6.2 years (range, 0-15). A total of 561 deaths (180 during 
the follow-up period in the original trial and 381 during the 
extended follow-up period) occurred: 284 deaths (25%) in 
the PCI group and 277 (24%) in the medical-therapy group 
(adjusted hazard ratio, 1.03; P=NS) (Sedlis SP et al, N Engl J 
Med 2015; 373:1937-1946).
LEADERS FREE: Among Patients at High Bleeding 
Risk Who Underwent PCI, a Polymer-Free  
Umirolimus (Biolimus A9)-Coated Stent was  
Superior to a Bare-Metal Stent When Used With  
a 1-Month Course of Dual Antiplatelet Therapy
A total of 2466 patients at high bleeding risk undergoing 
PCI, were randomized to a drug-coated stent or a bare-metal 
stent. The drug-coated stent was a polymer-free drug-coated 
stent that transfers umirolimus (biolimus A9), a highly lipo-
philic sirolimus analogue, into the vessel wall over 1 month. 
All patients received 1 month of dual antiplatelet therapy. 
At 390 days, the primary safety end point (cardiac death, MI, 
or stent thrombosis) occurred in 112 patients (9.4%) in the 
drug-coated–stent group and in 154 patients (12.9%) in the 
bare-metal–stent group (hazard ratio - HR, 0.71; P <0.001 
for noninferiority; P=0.005 for superiority). During the same 
period, clinically driven target-lesion revascularization was 
needed in 59 patients (5.1%) in the drug-coated–stent group 
and in 113 patients (9.8%) in the bare-metal–stent group 
(HR, 0.50; P <0.001) (Urban P et al, N Engl J Med 2015; 
373:2038-2047). 
Possible Subclinical Leaflet Thrombosis in 
Bioprosthetic Aortic Valves Suspected from Reduced 
Leaflet Motion Detected by 4-Dimensional, Volume-
Rendered CT / Therapeutic Anticoagulation With 
Warfarin, but not Therapy With Antiplatelet Drugs, 
Prevented and Effectively Treated This Phenomenon
Data obtained from 55 patients in a clinical trial of TAVI 
and from 2 registries that included 132 patients who were un-
dergoing either transcatheter (TAVI) or surgical aortic-valve 
bioprosthesis implantation showed reduced leaflet motion 
noted on computed tomography (CT) in 22 of 55 patients (40%) 
in the clinical trial and in 17 of 132 patients (13%) in the 2 
registries. Therapeutic anticoagulation with warfarin, as com-
pared with dual antiplatelet therapy, decreased the incidence 
of reduced leaflet motion (0% and 55%, respectively, P=0.01 
in the clinical trial; and 0% and 29%, respectively, P=0.04 in 
the pooled registries). In patients who were reevaluated with 
follow-up CT, restoration of leaflet motion was noted in all 
11 patients who were receiving anticoagulation and in 1 of 10 
patients who were not (P <0.001). There was no significant 
difference in the incidence of stroke or TIA between the two 
groups in the clinical trial (2 of 22 patients and 0 of 33 patients, 
respectively; P=NS), but in the registries, a significant dif-
ference was detected (3 of 17 patients and 1 of 115 patients, 
respectively; P=0.007) (Makkar RR et al, N Engl J Med 2015; 
373:2015-2024).
SPRINT Trial: Intensive (<120 mmHg)  
vs Standard (<140 mmHg) Blood-Pressure (BP) 
Control is Superior in Patients at High Risk  
for Cardiovascular Events but Without Diabetes,  
Albeit With Higher Rates of Some Adverse Events 
Patients (n=9361) with a systolic BP of >130 mmHg and 
an increased cardiovascular risk, but without diabetes, were 
randomized to a systolic BP target of <120 mmHg (n=4678, 
intensive treatment) or a target of <140 mmHg (n=4683, 
standard treatment). At 1 year, the mean systolic BP was 121.4 
mm Hg in the intensive-treatment and 136.2 mmHg in the 
standard-treatment group. Trial was stopped early (median 
3.26 years) due to significantly lower rate of the primary com-
posite outcome (myocardial infarction, other acute coronary 
syndromes, stroke, heart failure, or death from cardiovascular 
causes) in the intensive-treatment group (1.65% vs 2.19%/
year; hazard ratio - HR, 0.75; P <0.001). All-cause mortality 
was also significantly lower in the intensive-treatment group 
(HR, 0.73; P=0.003). Rates of serious adverse events (hypo-
tension, syncope, electrolyte abnormalities, and acute kidney 
injury or failure, but not of traumatic falls) were higher in the 
intensive-treatment group (SPRINT Research Group, N Engl 
J Med 2015; 373:2103-2116).
EMPA-REG OUTCOME Trial: Empagliflozin 
(Inhibitor of Sodium–Glucose Cotransporter 2)  
Added to Standard Care Confers Cardiovascular 
Benefit in Patients with Type 2 Diabetes 
A total of 7020 patients were randomly treated with 10 mg 
or 25 mg of empagliflozin or placebo (median observation time, 
3.1 years). The primary outcome (death from cardiovascular 
causes, nonfatal MI, or nonfatal stroke) occurred in 490 of 
4687 patients (10.5%) in the pooled empagliflozin group and 
in 282 of 2333 patients (12.1%) in the placebo group (hazard 
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ratio, 0.86; P=0.04 for superiority). There were no significant 
between-group differences in the rates of MI or stroke, but in 
the empagliflozin group there were significantly lower rates 
of death from cardiovascular causes (3.7%, vs 5.9% in the 
placebo group; 38% relative risk reduction), hospitalization 
for heart failure (2.7% and 4.1%, respectively; 35% relative 
risk reduction), and death from any cause (5.7% and 8.3%, 
respectively; 32% relative risk reduction). There was no sig-
nificant between-group difference in the secondary outcome 
(primary outcome plus hospitalization for unstable angina) 
(P=0.08 for superiority). Among patients receiving empagli-
flozin, there was an increased rate of genital infection but no 
increase in other adverse events (Zinman B et al, N Engl J Med 
2015; 373:2117-2128).
Toxic Central Obesity (NHANES III):  
Normal-Weight Central Obesity is associated  
with Higher Mortality than BMI-Defined  
(but no Central) Obesity 
Among 15,184 adults (aged 18-90 years; 52% women), 
persons with normal-weight central obesity had the worst 
long-term survival: a man with a normal BMI (22 kg/m2) and 
central obesity had greater total mortality risk than one with 
similar BMI but no central obesity (hazard ratio - HR, 1.87), 
and this man had twice the mortality risk of those who were 
overweight or obese by BMI only (HR, 2.24 & 2.42, respec-
tively). Women with normal-weight central obesity also had 
a higher mortality risk than those with similar BMI but no 
central obesity (HR, 1.48) and those who were obese accord-
ing to BMI only (HR, 1.32). Expected survival estimates were 
consistently lower for those with central obesity when age and 
BMI were controlled for (Sahakyan KR et al, Ann Intern Med. 
2015; 163:827-835). 
ROC Trial: In Patients With Out-Of-Hospital  
Cardiac Arrest, Continuous Chest Compressions 
During CPR did not Result in Significantly Higher 
Rates of Survival or Favorable Neurologic Function 
than did Interrupted Chest Compressions
Of 23,711 adults with non–trauma-related cardiac ar-
rest, 12,653 were assigned to continuous chest compres-
sions (intervention group) and 11,058 to interrupted chest 
compressions at a ratio of 30 compressions to 2 ventilations 
(control group). A total of 1129 of 12,613 patients with 
available data (9%) in the intervention group and 1072 of 
11,035 (9.7%) in the control group survived until discharge 
(P=0.07); 7% of the patients in the intervention group and 
7.7% of those in the control group survived with favorable 
neurologic function at discharge (P=0.09). Hospital-free 
survival was significantly shorter in the intervention group 
than in the control group (P=0.004) (Nichol G et al, N Engl 
J Med 2015; 373:2203-2214). 
ANNEXA-A and ANNEXA-R Trials: Andexanet 
Alfa Reversed the Anticoagulant Activity of Factor 
Xa Inhibitors, Apixaban and Rivaroxaban, in 
Older Healthy Participants Within Minutes After 
Administration and for the Duration of Infusion, 
Without Evidence of Clinical Toxic Effects 
Healthy older (mean age 58 years) volunteers were given 
5 mg of apixaban bid or 20 mg of rivaroxaban qd. Andexanet 
was administered as a bolus or as a bolus plus a 2-h infusion. 
Among the apixaban-treated participants, anti–factor Xa 
activity was reduced by 94% with andexanet bolus (n=24), 
vs 21% with placebo (n=9) (P <0.001), and unbound apixa-
ban concentration was reduced by 9.3 ng/ml vs 1.9 ng/ml (P 
<0.001); thrombin generation was fully restored in 100% vs 
11% of the participants (P <0.001) within 2-5 min. Among 
the rivaroxaban-treated participants, anti–factor Xa activity 
was reduced by 92% with andexanet bolus (n=27) vs 18% 
with placebo (n=14) (P <0.001), and unbound rivaroxaban 
concentration was reduced by 23.4 ng/ml vs 4.2 ng/ml (P 
<0.001); thrombin generation was fully restored in 96% vs 7% 
of the participants (P <0.001). These effects were sustained 
with andexanet bolus plus infusion. In a subgroup, transient 
increases in levels of d-dimer and prothrombin fragments 1 
and 2 were observed, which resolved within 24-72 h. No serious 
adverse or thrombotic events were reported (Siegal DM et al, 
N Engl J Med 2015; 373:2413-2424).
IPD-Work Consortium: Long Working Hours 
Increase Risk of Stroke and Less So Coronary Heart 
Disease Risk / More Attention Should Be Paid to the 
Management of Vascular Risk Factors in Individuals 
Who Work Long Hours 
Meta-analysis of 25 studies comprised data for 603,838 
men and women who were free from coronary heart disease at 
baseline, and data for 528,908 men and women who were free 
from stroke at baseline. Mean follow-up for coronary heart 
disease was 8.5 years, in which 4768 events were recorded, 
and for stroke 7.2 years, in which 1722 events were recorded. 
Compared with standard hours (35–40 h/week), working long 
hours (≥55 h/week) was associated with an increase in risk 
of coronary heart disease (relative risk - RR 1.13; p=0.02) 
and stroke (1.33; p=0.002). A dose–response association was 
recorded for stroke, with RR estimates of 1.10 (p=0.24) for 
41–48 working hours, 1.27 (p=0.03) for 49–54 working hours, 
and 1.33 (p=0.002) for >55 working hours/week compared 
with standard working hours (ptrend <0.0001) (Kivimaki M et 
al, Lancet 2015; 386(No. 10005):1739–1746).
REVERT Trial: Postural Modification of Valsalva 
Maneuver Increases Conversion of Supraventricular 
Tachycardias (SVT) from 17% to 43%
A modified Valsalva maneuver (done semi-recumbent 
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with supine repositioning and passive leg raise immediately 
after the Valsalva strain) (n=214) was compared with a non-
modified version of the maneuver (n=214) in 428 patients 
presenting with SVT. 37 (17%) of those assigned to standard 
Valsalva achieved sinus rhythm compared with 93 (43%) of 
214 in the modified Valsalva maneuver group (odds ratio 
3.7; p <0.0001) (Appelboam A et al, Lancet 2015; 386, No. 
10005:1747–1753). 
FAME Study 5-Year Follow-Up: Fractional Flow 
Reserve (FFR)-Guided PCI Conferred a Decrease of 
Major Adverse Cardiac Events for up to 2 Years, at 
2-5 Years the Risks Were Similar / This Outcome was 
Achieved With a Lower Number of Stented Arteries and 
Less Resource Use / FFR Guidance of Multivessel PCI 
Could be the Standard of Care in Most Patients
In FAME, fractional flow reserve (FFR)-guided percutane-
ous coronary intervention (PCI) (PCI done only if FFR was 
<0.80) improved outcome compared with angiography-guided 
PCI for up to 2 years of follow-up. After 5 years, major adverse 
cardiac events occurred in 31% of patients (154 of 496) in the 
angiography-guided group vs 28% (143 of 509 patients) in the 
FFR-guided group (relative risk 0.91; p=NS). The number 
of stents placed per patient was significantly higher in the 
angiography-guided than in the FFR-guided group (mean 2.7 
vs 1.9, p <0.0001) (van Nunen LX et al, Lancet 2015; 386, No. 
10006:1853–1860).
Spironolactone vs Placebo, Bisoprolol, and Doxazosin 
for Drug-Resistant Hypertension (PATHWAY-2): 
Spironolactone was the Most Effective Add-On Drug, 
Supporting a Primary Role of Sodium Retention in 
Resistant Hypertension
Patients (n=335), aged 18–79 years with seated clinic sys-
tolic blood pressure (BP) >140 mmHg (or ≥135 mm Hg for 
patients with diabetes) and home systolic BP (18 readings over 
4 days) >130 mmHg, despite treatment for at least 3 months 
with maximally tolerated doses of 3 drugs, were rotated, in a 
preassigned, randomized order, through 12 weeks of once daily 
treatment with each of spironolactone (25–50 mg) (n=285), 
bisoprolol (5–10 mg) (n=285), doxazosin modified release 
(4–8 mg) (n=282), and placebo (n=274), in addition to their 
baseline BP drugs. The dose was doubled after 6 weeks of 
each cycle; 230 patients completed all treatment cycles. The 
average reduction in home systolic BP by spironolactone was 
superior to placebo (–8.70 mmHg; p <0.0001), superior to the 
mean of the other 2 active treatments (doxazosin and bisopro-
lol; −4.26; p <0.0001), and superior when compared with the 
individual treatments; vs doxazosin (–4.03; p <0.0001) and vs 
bisoprolol (–4.48; p <0.0001). Spironolactone was the most 
effective BP-lowering treatment, throughout the distribution 
of baseline plasma renin; but its margin of superiority and 
likelihood of being the best drug for the individual patient 
were many-fold greater in the lower than higher ends of the 
distribution. All treatments were well tolerated. In 6 of the 
285 patients who received spironolactone, serum potassium 
exceeded 6 mmol/L on one occasion (Williams B et al, Lancet 
2015; 386, No. 10008:2059–2068).
CLEAN Trial: Chlorhexidine–Alcohol Appears More 
Effective than Povidone Iodine–Alcohol as a Skin 
Antiseptic to Prevent Intravascular-Catheter-Related 
Infections, Albeit With More Severe Skin Reactions
A total of 1181 patients (2547 catheters) were randomly 
assigned to 2% chlorhexidine–70% alcohol (594 patients with 
scrubbing, 587 without) and 1168 (2612 catheters) to 5% povi-
done iodine–69% alcohol (580 patients with scrubbing, 588 
without). Chlorhexidine–alcohol was associated with lower 
incidence of catheter-related infections (0.28 vs 1.77 per 1000 
catheter-days with povidone iodine–alcohol; hazard ratio 0.15; 
p=0.0002). Scrubbing was not associated with a significant dif-
ference in catheter colonization (p=NS). No systemic adverse 
events were reported, but severe skin reactions occurred more 
frequently in those assigned to chlorhexidine–alcohol (27 or 3% 
patients vs 7 or 1% with povidone iodine–alcohol; p=0.0017) 
and led to chlorhexidine discontinuation in 2 patients (Mimoz 
O et al, Lancet 2015; 386, No. 10008:2069–2077).
Review & Meta-Analysis: Transradial Access  
for Coronary Angiography and Percutaneous  
Coronary Intervention (PCI) is Associated with  
a Small but Significant Increase in Radiation  
Exposure in Both Diagnostic and Interventional 
Procedures Compared With Transfemoral Access / 
Differences in Radiation Exposure Narrowed  
Over Time
Data from 24 randomized controlled trials (RCTs) for 
19,328 patients showed that transradial access was associated 
with a small but significant increase in fluoroscopy time for 
coronary angiograms (weighted mean difference - WMD, fixed 
effect: 1.04 min; p <0.0001) and PCI (1.15 min; p <0.0001), 
compared with transfemoral access. Transradial access was 
also associated with higher kerma (gray-Gy)-area product 
for coronary angiograms (WMD, fixed effect: 1.72 Gy·cm2; 
p=0.06), and higher kerma-area product for PCI (0.55 Gy·cm2; 
p=0.02). Operator radiation doses for PCI with basic protec-
tion were 107+110 μSv with transradial and 74+68 μSv with 
transfemoral access; with supplementary protection, the doses 
decreased to 21+17 μSv with transradial access and 46+9 
μSv with transfemoral. Overall difference in fluoroscopy 
time between the 2 procedures has decreased significantly 
by 75% over the past 20 years from 2 min in 1996 to ~30 s 
in 2014 (p <0.0001) (Plourde G et al, Lancet 2015; 386, No. 
10009:2192–2203).
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High-STEACS Trial: Low Plasma Levels of High-
Sensitivity Troponin at Presentation in Patients With 
Suspected Acute Coronary Syndrome Identify Two-
Thirds of Patients at Very Low Risk of Cardiac Events 
Who Could be Discharged From Hospital
According to a prospective study of 6304 consecutive pa-
tients with suspected acute coronary syndrome, 782 (16%) of 
4870 patients in the derivation cohort having MI, with a further 
32 (1%) re-presenting with MI and 75 (2%) cardiac deaths at 
30 days, in patients without MI at presentation, troponin con-
centrations were <5 ng/L in 2311 (61%) of 3799 patients, with 
a negative predictive value of 99.6% for the primary outcome 
(MI or subsequent MI or cardiac death at 1 month). The nega-
tive predictive value was consistent across groups stratified by 
age, sex, risk factors, and previous cardiovascular disease. In 
two independent validation cohorts, troponin concentrations 
were <5 ng/L in 594 (56%) of 1061 patients, with an overall 
negative predictive value of 99.4%. At 1 year, these patients 
had a lower risk of MI and cardiac death than did those with 
a troponin concentration of >5 ng/L (0.6% vs 3.3%; adjusted 
hazard ratio 0.41; p <0.0001) (Shah ASV et al, Lancet 2015; 
386, No. 10012: 2481–2488). 
Danish Cohort Study: In a Real-World Cohort of 
Patients with a First Hospitalization for an Acute 
Coronary Syndrome (ACS), Early Invasive Treatment 
Strategy was Associated With a Lower Risk for Cardiac 
Death and Rehospitalization for MI Compared with a 
Conservative Invasive Approach
In 19,704 propensity score–matched patients hospitalized 
with a first ACS, compared with a conservative approach, early 
invasive strategies were associated with a lower risk for cardiac 
death (cumulative incidence, 5.9% vs 7.6%; hazard ratio - HR, 
0.75; P < 0.001). Similar results were found for rehospitaliza-
tion for MI (cumulative incidence, 3.4% vs 50%; HR, 0.67; P 
< 0.001) and all-cause death (cumulative incidence, 7.3% vs. 
10.6%; HR, 0.65; P <0.001) (Hansen KW et al, Ann Intern 
Med 2015; 163:737-746). 
In Digoxin Users Variant Alleles at Each of the 3 Loci 
in the ABCB1 Gene were Associated with an Increased 
Risk of SCD Compared With those with None or One T 
Allele, Implying that the ABCB1 Genotype Modifies the 
Risk of Cardiac Toxicity by Digoxin
The ATP-binding cassette B1 (ABCB1) gene encodes P-
glycoprotein, a transport protein playing an important role in 
the bioavailability of digoxin. In a total of 10,932 persons (>45 
years), 419 sudden cardiac deaths (SCDs) occurred during a 
median of 9.8 years. In non-users of digoxin, the risk of SCD 
was not different across genotypes. In digoxin users, homozy-
gous T allele carriers of C1236T (HR 1.90; allele frequency 
0.43), G2677T (HR 1.89; allele frequency 0.44) and C3435T 
(HR 1.72; allele frequency 0.53) had a significantly increased 
risk of SCD (Niemeijer MN et al, Heart 2015; 101:1973-1979). 
Sweetened Beverage Consumption is Associated With 
Higher Risk of Heart Failure (HF), Possibly Having 
Implications for HF Prevention Strategies
Among 42,400 Swedish men, aged 45-79 years, during a 
mean follow-up of 11.7 years, a total of 4113 HF events were 
identified. A positive association was observed between sweet-
ened beverage consumption and risk of HF after adjustment 
for other risk factors (p for trend <0.001). Men who consumed 
>2 servings of sweetened beverages per day had a significantly 
higher risk of developing HF (23%) compared to men who were 
non-consumers (Rahman I et al, Heart 2015; 101:1961-1965). 
Micra Pacing Study: Transcatheter Leadless Pacing 
Can Safely and Effectively be Applied
Patients (n=140) requiring a VVI pacer underwent im-
plantation of the Micra transcatheter pacing system, from the 
femoral vein, fixed in the right ventricle using 4 protractible 
nitinol tines. Over 1.9±1.8 months, 30 adverse events related 
to the system or procedure occurred, mostly due to transient 
dysrhythmias or femoral access complications. One pericardial 
effusion without tamponade occurred after 18 device deploy-
ments. In 60 patients followed to 3 months, mean pacing 
threshold was 0.51±0.22 V, and no threshold was ≥2 V. Average 
R-wave was 16.1±5.2 mV and impedance was 650.7±130 ohms 
(Ritter P et al, Eur Heart J 2015; 36:2510-2519). 
Long-Term Exposure to Road Traffic Noise was 
Associated with Small Increased Risks of All-Cause 
and Cardiovascular Mortality and Morbidity in the 
General Population, Particularly for Stroke in the 
Elderly
Median daytime exposure to road traffic noise in London 
(8.6 million inhabitants) was 55.6 dB. Daytime road traffic noise 
increased risk of hospital admission for stroke with relative 
risk (RR) 1.05 in adults, and 1.09 in the elderly in areas >60 
vs <55 dB. Nighttime noise was associated with stroke admis-
sions only among the elderly. Daytime noise was associated 
with all-cause mortality in adults (RR 1.04 in areas >60 vs 
<55 dB). Positive but non-significant associations were seen 
with mortality for cardiovascular and ischemic heart disease, 
and stroke (Halonen JI et al, Eur Heart J 2015; 36:2653-2661). 
Normalization of Testosterone Level is Associated with 
Reduced Incidence of Myocardial Infarction, Stroke 
and Mortality in Men
Of 3 groups (Gp) among 83,010 male veterans with low total 
testosterone (TT) levels, Gp1 with testosterone replacement 
therapy (TRT) and normalization of TT levels (n=43,931, 
median age = 66 years, mean follow-up = 6.2 years), Gp2 with 
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TRT but without normalization of TT levels (n=25,701, median 
age = 66 years, mean follow-up = 4.6 years), and Gp3 without 
TRT (n=13,378, median age = 66 years, mean follow-up = 
4.7 years), all-cause mortality (hazard ratio - HR: 0.44), risk 
of MI (HR: 0.76), and stroke (HR: 0.64) were lower in Gp1 
vs Gp3. Also, all-cause mortality (HR: 0.53), risk of MI (HR: 
0.82), and stroke (HR: 0.70) were lower in Gp1 vs Gp2. There 
was no difference in MI or stroke risk between Gp2 and Gp3 
(Sharma R et al, Eur Heart J 2015; 36:2706-2715). 
Reduced Appropriate Implantable Cardioverter-
Defibrillator (ICD) Therapy after Cardiac 
Resynchronization Therapy (CRT)-Induced Left 
Ventricular Function Recovery
In 6 retrospective cohort studies (n=1740), in patients with 
post-CRT LVEF ≥35%, rate of ICD therapy was significantly 
lower than patients with post-CRT LVEF <35%. Similarly, 
patients with post-CRT LVEF ≥45% had lower estimated 
rates of ICD therapy. Limiting analysis to studies discounting 
ICD therapies during LVEF recovery, patients with LVEF 
recovery (≥35 or ≥45%) had significantly lower rates of ICD 
therapy (Chatterjee NA et al, Eur Heart J 2015; 36:2780-2789). 
CONTROL Study: Prostar XL-Based Vascular Closure 
in TAVI Procedures was Associated with More Major 
Vascular Complications Compared with ProGlide; 
However, In-Hospital Mortality was Similar
Among 3138 transfemoral TAVI patients (944 matched / 
472 pairs), major vascular complications or in-hospital mortality 
occurred more frequently in Prostar vs ProGlide group (9.5 
vs 5.1%, P=0.016), driven by higher rates of major vascular 
complication (7.4 vs 1.9%, P <0.001) in the Prostar group. 
However, in-hospital mortality was similar (4.9 vs 3.5%, P=0.2). 
Femoral artery stenosis occurred less frequently in the Prostar 
group (3.4 vs 0.5%, P=0.004), but overall, Prostar use was as-
sociated with higher rates of major bleeding (16.7 vs 3.2%, P 
<0.001), acute kidney injury (17.6 vs 4.4%, P <0.001) and with 
longer hospital stay (median 6 vs 5 days, P=0.007) (Barbash 
IM et al, Eur Heart J 2015; 36:3370-3379).
Important Review and Other Articles
2015 International Consensus on Cardiopulmonary Resusci-
tation (Circulation 2015;132: suppl 1 S2-S268), 2015 American 
Heart Association Guidelines Update for Cardiopulmonary 
Resuscitation (Circulation 2015;132: suppl 2 S315-S573), AHA/
ACC Scientific Statement on Eligibility and Disqualification 
Recommendations for Competitive Athletes With Cardiovascular 
Abnormalities (Circulation 2015; 132:e256-e349 and J Am Coll 
Cardiol 2015; 66:2343-2450), Arrhythmia-induced cardiomyo-
pathies (Gopinathannair R et al, J Am Coll Cardiol 2015; 
66:1714-1728), Percutaneous pulmonary valve implantation 
(Ansari MM et al, J Am Coll Cardiol 2015; 66:2246-2255), 
Transthyretin amyloidosis (Gertz MA et al, J Am Coll Cardiol 
2015; 66:2451-2466), Hemodynamics of mechanical circulatory 
support (Burkhoff D et al, J Am Coll Cardiol 2015; 66:2663-
2674), 2015 ACC/AHA/HRS Advanced Training Statement on 
Clinical Cardiac Electrophysiology (Zipes DP et al, J Am Coll 
Cardiol 2015; 66:2767-2802), Risk factor modification in AF 
(Miller JD et al, J Am Coll Cardiol 2015; 66:2899-2906), Car-
diovascular management in pregnancy: antithrombotic agents 
and antiplatelet agents (Yarrington CD et al, Circulation 2015; 
132:1354-1364), AHA Statement on infective endocarditis (Cir-
culation 2015; 132:1435-1486 & 1487-1515), PCSK-9 inhibitors 
(Bergeron N et al, Circulation 2015; 132:1648-1666), Cardiac 
arrest in pregnancy (Jeejeebhoy FM et al, Circulation 2015; 
132:1747-1773), Contrast-induced nephropathy (Wichmann JL 
et al, Circulation 2015; 132:1931-1936), Pediatric pulmonary 
hypertension (Abman SH et al, Circulation 2015; 132:2037-
2099), Cardio-Oncology (Bellinger AM et al, Circulation 2015; 
132:2248-2258), Cardiovascular implications of hypoglycemia 
(Connelly KA et al, Circulation 2015; 132:2345-2350), Idaruci-
zumab (Eikelboom JW et al, Circulation 2015; 132:2412-2422), 
Cardiac complications in non-cardiac surgery (Devereaux PJ 
& Sessler DI, N Engl J Med 2015; 373:2258-2269), Resistant 
hypertension in chronic kidney disease (Rossignol P et al, 
Lancet 2013; 386:1588–1598), Role of ambulatory and home 
blood pressure monitoring in clinical practice (Shimbo D et 
al, Ann Intern Med 2015; 163:691-700), Pulmonary embolism 
guidelines (Raja AS et al, Ann Intern Med 2015; 163:701-711), 
Blood pressure screening (Siu AL et al, Ann Intern Med 2015; 
163:778-786), Radial vs femoral access in ACS (Ando G & 
Capodanno D et al, Ann Intern Med 2015; 163:932-940), Patent 
foramen ovale (Asrress KN et al, Heart 2015; 101:1916-1925), 
When to consider an ICD following MI (Szwejkowski BR et al, 
Heart 2015; 101:1996-2000), Resistant hypertension (Rimoldi 
SF et al, Eur Heart J 2015; 36:2686-2695), 2015 ESC guidelines 
for the management of infective endocarditis (Habib G et al, 
Eur Heart J 2015; 36:3075-3128), Treatment of arrhythmogenic 
right ventricular dysplasia (Corrado D et al, Eur Heart J 2015; 
36:3227-3237).
